about
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma.Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia.Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.Brain metastases from colorectal carcinoma: prognostic factors and outcome.High KLF4 level in normal tissue predicts poor survival in colorectal cancer patientsThe role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study.Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experienceClinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites.Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and ChildrenUpfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastasesNovel methods for clinical risk stratification in patients with colorectal liver metastasesMRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection.Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors.Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trialp16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal CancerA phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience.Circumferential resection margin positivity after preoperative chemoradiotherapy based on magnetic resonance imaging for locally advanced rectal cancer: implication of boost radiotherapy to the involved mesorectal fasciaEffects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers.Prognostic implications of PIK3CA amplification in curatively resected liposarcomaDynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.Clinical value of ezrin expression in primary osteosarcoma.Single immunochemical fecal occult blood test for detection of colorectal neoplasia.Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition.High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer.PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity.Reduced pelvic field sparing anastomosis for postoperative radiotherapy in selected patients with mid-upper rectal cancerGenome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis.Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients.A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer.Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery.S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer.A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
P50
Q33396613-03900B7E-F63B-4A57-AC2E-9B20DA3B5003Q33410008-508BB106-2FFC-46E3-BA87-6C9B5AB55530Q33410206-90FD8603-6234-4D0F-B4F3-242ABDFAB320Q33557905-540C9E43-4C3B-47A7-B7AD-E257348A4A53Q33566877-C152A3FC-CAA4-4F25-ACEC-75CF5D702696Q33577959-B0103D0B-812F-4909-8877-CF6FE3C21017Q33990397-BC29B925-E070-4913-9C14-E000FE9EADD6Q34137566-868A30B8-AAFB-471C-BFF7-5D36EBBCDB81Q34444374-8B5051AB-CE06-4F39-9E3E-611FD105DD48Q34494770-153CF96C-AACB-46A7-9C6C-5F2B6E131A8BQ34977196-0808F12D-E496-44EE-A01B-8596CF3BFDF2Q35206160-B3AA6BD0-8E71-4C18-B554-C8EB7083D900Q35429661-470C3851-1D72-4CFB-AA0A-16619B4ED55FQ35885124-34F285C9-ADDF-432A-8788-BE7F072D94C1Q36072022-1E7A61D9-EB26-43BB-9284-DDBE94E9C142Q36106616-3B89777C-819E-4D33-A3DF-653D5BF91376Q36187013-7439944B-AF13-42D2-A408-AC5FCA6E5529Q36476152-DB166903-15AF-4277-A835-0BDFDEE29276Q36482470-C6F6FFD8-9CCC-4151-93F1-CFCB4E3B4C9EQ36612624-171775CA-1655-4853-A4E7-E45FD4A1F96EQ36786775-3960229D-8EB8-43BA-9AE3-7B8A163DE4FBQ36949323-03CEE4B2-8865-4520-A8D8-A2B35AE52530Q37061363-8E7F31B1-B483-4981-9C36-0E4C7DDCAF2AQ37269360-72EAF382-B9D8-4F75-8B9C-4ED643298BDCQ37367448-631DFE4B-3288-4DBB-82B2-FC0AE2656DE0Q37376890-0CDF1605-5A2B-4460-887F-CC4787CE5744Q37447039-73FDA1E4-8E9B-4E32-A78C-948338289EBBQ38457404-F1F41646-E598-4D33-96DC-E99684642088Q38731875-ED7D33A2-51FD-42BB-8FF0-E830BBB78EDCQ38838849-DFDAFB5A-6517-4285-9301-B1633A6534C0Q38945020-1C8F472D-0DB0-44C8-80AC-B3939846B353Q39103454-A89BDE1E-1468-472A-931D-FD7528DD5545Q39612136-5FB450B5-BDDC-4240-B141-48909703DCACQ39822963-41FE9CEE-99C0-4545-9071-6DE5004517ABQ39827658-A55DD9A1-404D-4A9F-B6E7-214C0E4CBC84Q41115604-F6E5524D-7E9B-465D-8453-1D4496B2BE2EQ41145098-2BE88C8E-BCEA-4B1F-82AB-5D4D43D15262Q41594853-0147D6E9-E550-4AED-AF07-8719FE077525Q41907282-543DA931-163E-49BD-BFFD-2D60C373DF7EQ42770955-4FDF7F99-6088-41F1-BDEC-1943213A76B6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joong Bae Ahn
@ast
Joong Bae Ahn
@en
Joong Bae Ahn
@es
Joong Bae Ahn
@nl
type
label
Joong Bae Ahn
@ast
Joong Bae Ahn
@en
Joong Bae Ahn
@es
Joong Bae Ahn
@nl
prefLabel
Joong Bae Ahn
@ast
Joong Bae Ahn
@en
Joong Bae Ahn
@es
Joong Bae Ahn
@nl
P106
P31
P496
0000-0001-6787-1503